Ekso Bionics Stock Fair Value – EKSO BIONICS Anticipates Revenues of $4.7M-$4.9M for Q4
January 5, 2024
🌥️Trending News
Ekso Bionics ($NASDAQ:EKSO), a company that develops and manufactures exoskeleton technology, has announced that they anticipate their fourth quarter revenue will be between $4.7M and $4.9M. Ekso Bionics works to improve the lives of people with mobility impairments by providing exoskeleton technologies that enable them to stand up and walk with assistance. The company has developed a portfolio of products ranging from medical devices to powered industrial exoskeletons and has partnered with multiple medical facilities and defense organizations to provide solutions for those who need it the most. With their anticipated fourth quarter revenues, Ekso Bionics continues to demonstrate their commitment to innovation and their dedication to helping individuals with mobility impairments.
Earnings
In the latest earnings report of FY2023 Q3 ending September 30 2021, EKSO BIONICS reported a total revenue of 3.05M USD, representing a 8.4% decrease compared to the previous year. Despite this decline, the company has seen an overall from 3.05M USD to 4.61M USD in total revenue over the last three years. However, the company also reported a net income loss of 1.96M USD. This shows the company’s commitment to continuing its success in the coming quarter and beyond.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Ekso Bionics. More…
| Total Revenues | Net Income | Net Margin |
| 16.98 | -15.16 | -97.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ekso Bionics. More…
| Operations | Investing | Financing |
| -14.11 | -5.15 | 0 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ekso Bionics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 31.18 | 15.93 | 1.07 |
Key Ratios Snapshot
Some of the financial key ratios for Ekso Bionics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 18.0% | – | -87.5% |
| FCF Margin | ROE | ROA |
| -84.1% | -56.2% | -29.8% |
Market Price
On Thursday, EKSO BIONICS announced its expectations for its fourth quarter revenues, which it anticipates will be between $4.7M and $4.9M. This announcement came after the stock opened at $2.7 and closed at $2.5, down by 4.2% from last closing price of 2.6. Though the news of anticipated revenues was a positive sign for the company, the stock prices reacted negatively to the announcement and saw a drop in their prices.
This decline could be due to investors’ concerns over the company’s future prospects or other economic factors at play. Nevertheless, EKSO BIONICS still remains a strong presence in the medical technology industry and is poised to take advantage of any new opportunities that may arise in the near future. Live Quote…
Analysis – Ekso Bionics Stock Fair Value
At GoodWhale, we have conducted an analysis of EKSO BIONICS‘s financials. According to our proprietary Valuation Line, the intrinsic value of an EKSO BIONICS share is around $3.8. This means that, at the current trading price of $2.5, EKSO BIONICS stock is undervalued by 34.8%. This presents an excellent opportunity for investors to capitalize on the potential upside of this stock. More…
Peers
– AngioDynamics Inc ($NASDAQ:ANGO)
AngioDynamics Inc is a medical device company that focuses on developing, manufacturing, and marketing innovative medical, surgical, and diagnostic devices used by healthcare professionals for the treatment of peripheral vascular disease, as well as tumors in the liver, kidney, and bone. As of 2023, AngioDynamics has a market capitalization of 325.27M. Its current Return on Equity is -5.72%. This suggests that AngioDynamics has not been successful in generating profits from its investments in the past few years. Despite this, the company continues to focus on providing innovative and effective solutions for its customers.
– Hogy Medical Co Ltd ($TSE:3593)
Hogy Medical Co Ltd is a healthcare company that provides healthcare products and services to the public. Founded in 2002, its market cap as of 2023 stands at 82.47B USD. Its Return on Equity (ROE) is 4.83%, which is an indication that the company is able to generate positive returns on the capital shareholders have provided. This is a positive sign for company performance and a sign of growth. Hogy Medical Co Ltd continues to expand its offerings and strives to provide quality healthcare products and services to its customers.
– Atrion Corp ($NASDAQ:ATRI)
Atrion Corp is a medical device company that specializes in ophthalmic, cardiovascular, and fluid delivery products. With a market cap of 1.09B as of 2023, Atrion Corp is a sizeable player in the medical device industry. Additionally, the company boasts a Return on Equity (ROE) of 10.21%, indicating that the company is performing better than its peers. This strong financial performance is indicative of the successful products and services that Atrion Corp provides to its customers.
Summary
Following this announcement, the company’s stock price dropped significantly. However, due to potential benefits from their new exoskeleton rental and financing programs, and their strong foothold in the medical, military, industrial, and consumer markets, Ekso Bionics could still be a strong investment opportunity for those looking to diversify their portfolio. Furthermore, Ekso Bionics is focusing on expanding their global market presence and partnerships with industry leaders. With their innovative technology and diverse customer base, Ekso Bionics could have long-term prospects for investors.
